Synthesis and in-silico Studies of 4-phenyl thiazol-2-amine Derivatives as Putative Anti-breast Cancer Agents


Cite item

Full Text

Abstract

Background:Breast cancer (BC) is the second-leading cause of cancer-related fatalities in women after lung cancer worldwide. The development of BC is significantly influenced by estrogen receptors (ERs). The problem with current cancer treatments is selectivity, target specificity, cytotoxicity, and developing resistance. Thiazole scaffolds are gaining popularity in drug discovery due to their broad range of biological activity. It has the extraordinary capacity to control a variety of cellular pathways, and its potential for selective anticancer activity can be explored.

Objectives:Synthesis and in-silico studies of 4-Phenyl thiazol-2-amine derivatives as anti-breast cancer agents and molecular docking was used to assess the compounds’ capacity to bind ER-α protein target.

Methods:In this study, 4-Phenylthiazol-2-amine derivatives (3a-j) have been synthesized, and using Schrodinger software, molecular docking and ADME studies of the compounds were conducted.

Results:Most of the synthesized compounds have shown dock scores ranging from -6.658 to - 8.911 kcal/mol, which is better than the standard drug tamoxifen (-6.821 kcal/mol). According to molecular docking, all compounds fit in the protein’s active site and have the same hydrophobic pocket as the standard drug tamoxifen. Further, all of the compounds’ ADME properties are below acceptable limits.

Conclusion:Compound 3e showed the best docking score of -8.911. All compounds’ ADME properties are within acceptable limits, and their p/o coefficients fall within a range, suggesting they will all have sufficient absorption at the site of action. These compounds can be evaluated invitro and in-vivo in the future.

About the authors

Kanamarlapudi Lavanya

Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab

Email: info@benthamscience.net

Kamalpreet Kaur

Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab

Email: info@benthamscience.net

Vikas Jaitak

Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab

Author for correspondence.
Email: info@benthamscience.net

References

  1. Ayati, A.; Emami, S.; Moghimi, S.; Foroumadi, A. Thiazole in the targeted anticancer drug discovery. Future Med. Chem., 2019, 11(15), 1929-1952. doi: 10.4155/fmc-2018-0416 PMID: 31313595
  2. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin., 2022, 72(1), 7-33. doi: 10.3322/caac.21708 PMID: 35020204
  3. Uhlen, M.; Zhang, C.; Lee, S.; Sjöstedt, E.; Fagerberg, L.; Bidkhori, G.; Benfeitas, R.; Arif, M.; Liu, Z.; Edfors, F.; Sanli, K.; von Feilitzen, K.; Oksvold, P.; Lundberg, E.; Hober, S.; Nilsson, P.; Mattsson, J.; Schwenk, J.M.; Brunnström, H.; Glimelius, B.; Sjöblom, T.; Edqvist, P.H.; Djureinovic, D.; Micke, P.; Lindskog, C.; Mardinoglu, A.; Ponten, F. A pathology atlas of the human cancer transcriptome. Science, 2017, 357(6352), eaan2507. doi: 10.1126/science.aan2507 PMID: 28818916
  4. Dandriyal, R.; Pandit, N.; Rao, S.C.; Sapra, G.; Sharma, H.; Agarwal, U. Psammomatoid juvenile aggressive ossifying fibroma of mandible. Natl. J. Maxillofac. Surg., 2012, 3(1), 47-50. doi: 10.4103/0975-5950.102155 PMID: 23251058
  5. Li, C.I.; Uribe, D.J.; Daling, J.R. Clinical characteristics of different histologic types of breast cancer. Br. J. Cancer, 2005, 93(9), 1046-1052. doi: 10.1038/sj.bjc.6602787 PMID: 16175185
  6. Dossus, L.; Benusiglio, P.R. Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res., 2015, 17(1), 37. doi: 10.1186/s13058-015-0546-7 PMID: 25848941
  7. Blowman, K.; Magalhães, M.; Lemos, M.; Cabral, C.; Pires, I. Anticancer properties of essential oils and other natural products. Evid. Based Complement. Altern. Med., 2018, 2018.
  8. Patel, H.K.; Bihani, T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol. Ther., 2018, 186, 1-24. doi: 10.1016/j.pharmthera.2017.12.012 PMID: 29289555
  9. Martinkovich, S.; Shah, D.; Planey, S.L.; Arnott, J.A. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clin. Interv. Aging, 2014, 9, 1437-1452. PMID: 25210448
  10. Foryst-Ludwig, A.; Kintscher, U. Metabolic impact of estrogen signalling through ERalpha and ERbeta. J. Steroid Biochem. Mol. Biol., 2010, 122(1-3), 74-81. doi: 10.1016/j.jsbmb.2010.06.012 PMID: 20599505
  11. Jia, M.; Dahlman-Wright, K.; Gustafsson, J.Å. Estrogen receptor alpha and beta in health and disease. Best Pract. Res. Clin. Endocrinol. Metab., 2015, 29(4), 557-568. doi: 10.1016/j.beem.2015.04.008 PMID: 26303083
  12. Anbalagan, M.; Rowan, B.G. Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer. Mol. Cell. Endocrinol., 2015, 418(Pt 3), 264-272. doi: 10.1016/j.mce.2015.01.016 PMID: 25597633
  13. Lee, J.Y.; Kim, H.S.; Song, Y.S. Genistein as a potential anticancer agent against ovarian cancer. J. Tradit. Complement. Med., 2012, 2(2), 96-104. doi: 10.1016/S2225-4110(16)30082-7 PMID: 24716121
  14. Jordan, V.C.; Gapstur, S.; Morrow, M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J. Natl. Cancer Inst., 2001, 93(19), 1449-1457. doi: 10.1093/jnci/93.19.1449 PMID: 11584060
  15. Riggs, B.L.; Hartmann, L.C. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N. Engl. J. Med., 2003, 348(7), 618-629. doi: 10.1056/NEJMra022219 PMID: 12584371
  16. Yavropoulou, M.P.; Makras, P.; Anastasilakis, A.D. Bazedoxifene for the treatment of osteoporosis. Expert Opin. Pharmacother., 2019, 20(10), 1201-1210. doi: 10.1080/14656566.2019.1615882 PMID: 31091133
  17. Singh, A.K.; Raj, V.; Saha, S. Indole-fused azepines and analogues as anticancer lead molecules: Privileged findings and future directions. Eur. J. Med. Chem., 2017, 142, 244-265. doi: 10.1016/j.ejmech.2017.07.042 PMID: 28803677
  18. Dandriyal, J.; Kaur, K.; Jaitak, V. Synthesis and in silico studies of c-4 substituted coumarin analogues as anticancer agents. Curr. Computeraided Drug Des., 2021, 17(4), 560-570. doi: 10.2174/1573409916666200628104638 PMID: 32598267
  19. Ayati, A.; Emami, S.; Asadipour, A.; Shafiee, A.; Foroumadi, A. Recent applications of 1,3-thiazole core structure in the identification of new lead compounds and drug discovery. Eur. J. Med. Chem., 2015, 97, 699-718. doi: 10.1016/j.ejmech.2015.04.015 PMID: 25934508
  20. Kashyap, S.J.; Garg, V.K.; Sharma, P.K.; Kumar, N.; Dudhe, R.; Gupta, J.K. Thiazoles: having diverse biological activities. Med. Chem. Res., 2012, 21(8), 2123-2132. doi: 10.1007/s00044-011-9685-2
  21. Rouf, A.; Tanyeli, C. Bioactive thiazole and benzothiazole derivatives. Eur. J. Med. Chem., 2015, 97, 911-927. doi: 10.1016/j.ejmech.2014.10.058 PMID: 25455640
  22. Mishra, R.; Sharma, P.K.; Verma, P.K.; Tomer, I.; Mathur, G.; Dhakad, P.K. Biological potential of thiazole derivatives of synthetic origin. J. Heterocycl. Chem., 2017, 54(4), 2103-2116. doi: 10.1002/jhet.2827
  23. Jaitak, V. Sahil; Kaur, K. Thiazole and related heterocyclic systems as anticancer agents: A review on synthetic strategies, mechanisms of action and SAR studies. Curr. Med. Chem., 2022, 29(29), 4958-5009. doi: 10.2174/0929867329666220318100019 PMID: 35306982
  24. Sharma, P.C.; Bansal, K.K.; Sharma, A.; Sharma, D.; Deep, A. Thiazole-containing compounds as therapeutic targets for cancer therapy. Eur. J. Med. Chem., 2020, 188, 112016. doi: 10.1016/j.ejmech.2019.112016 PMID: 31926469
  25. El-Mawgoud, H.K.A. Synthesis, in-vitro cytotoxicity and antimicrobial evaluations of some novel thiazole based heterocycles. Chem. Pharm. Bull., 2019, 67(12), 1314-1323. doi: 10.1248/cpb.c19-00681 PMID: 31787658
  26. Liu, X.H.; Lv, P.C.; Xue, J.Y.; Song, B.A.; Zhu, H.L. Novel 2,4,5-trisubstituted oxazole derivatives: Synthesis and antiproliferative activity. Eur. J. Med. Chem., 2009, 44(10), 3930-3935. doi: 10.1016/j.ejmech.2009.04.019 PMID: 19423198
  27. Sun, M.; Xu, Q.; Xu, J.; Wu, Y.; Wang, Y.; Zuo, D.; Guan, Q.; Bao, K.; Wang, J.; Wu, Y.; Zhang, W. Synthesis and bioevaluation of N,4-diaryl-1,3-thiazole-2-amines as tubulin inhibitors with potent antiproliferative activity. PLoS One, 2017, 12(3), e0174006. doi: 10.1371/journal.pone.0174006 PMID: 28333984
  28. Macaev, F. What can be done with the acetyl group of aryl-1 ethanones? Chem. J. Moldova, 2006, 1(1), 36-49. doi: 10.19261/cjm.2006.01(1).10
  29. Friggeri, L.; Hargrove, T.Y.; Wawrzak, Z.; Blobaum, A.L.; Rachakonda, G.; Lindsley, C.W.; Villalta, F.; Nes, W.D.; Botta, M.; Guengerich, F.P.; Lepesheva, G.I. Sterol 14α-Demethylase structure-based design of VNI ((R)- N -(1-(2,4-Dichlorophenyl)-2-(1 H -imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) derivatives to target fungal infections: Synthesis, biological evaluation, and crystallographic analysis. J. Med. Chem., 2018, 61(13), 5679-5691. doi: 10.1021/acs.jmedchem.8b00641 PMID: 29894182
  30. Roy, K.K.; Singh, S.; Sharma, S.K.; Srivastava, R.; Chaturvedi, V.; Saxena, A.K. Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H37RV. Bioorg. Med. Chem. Lett., 2011, 21(18), 5589-5593. doi: 10.1016/j.bmcl.2011.06.076 PMID: 21783364
  31. Jeong, K.; Lee, J.; Park, S.; Choi, J.H.; Jeong, D.Y.; Choi, D.H.; Nam, Y.; Park, J.H.; Lee, K.N.; Kim, S.M.; Ku, J.M. Synthesis and in-vitro evaluation of 2-amino-4-arylthiazole as inhibitor of 3D polymerase against foot-and-mouth disease (FMD). Eur. J. Med. Chem., 2015, 102, 387-397. doi: 10.1016/j.ejmech.2015.08.020 PMID: 26301555
  32. Shaik, S.P.; Nayak, V.L.; Sultana, F.; Rao, A.V.S.; Shaik, A.B.; Babu, K.S.; Kamal, A. Design and synthesis of imidazo2,1-bthiazole linked triazole conjugates: Microtubule-destabilizing agents. Eur. J. Med. Chem., 2017, 126, 36-51. doi: 10.1016/j.ejmech.2016.09.060 PMID: 27744185
  33. Sim, M.; Lee, S.; Han, Y. Synthesis and structural confirmation of the thiazole alkaloids derived from Peganum harmala L. Appl. Sci., 2021, 12(1), 78. doi: 10.3390/app12010078
  34. Ali, S.H.; Sayed, A.R. Review of the synthesis and biological activity of thiazoles. Synth. Commun., 2021, 51(5), 670-700. doi: 10.1080/00397911.2020.1854787
  35. LigPrep; Schrödinger. LLC: New York, NY, USA, 2021.
  36. Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des., 2013, 27(3), 221-234. doi: 10.1007/s10822-013-9644-8 PMID: 23579614
  37. Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 2006, 49(21), 6177-6196. doi: 10.1021/jm051256o PMID: 17034125
  38. Halgren, T.A.; Murphy, R.B.; Friesner, R.A.; Beard, H.S.; Frye, L.L.; Pollard, W.T.; Banks, J.L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem., 2004, 47(7), 1750-1759. doi: 10.1021/jm030644s PMID: 15027866
  39. QikProp; Schrödinger. LLC: New York, NY, 2019.
  40. Hantzsch, A.; Weber, J.H. Ueber verbindungen des thiazols (pyridins der thiophenreihe). Ber. Dtsch. Chem. Ges., 1887, 20(2), 3118-3132. doi: 10.1002/cber.188702002200

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers